Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion

  • Barbero-Camps, Elisabet
  • Roca-Agujetas, Vicente
  • Bartolessis, Isabel
  • Dios, Cristina de
  • Fernández-Checa, José C.
  • Marí, Montserrat
  • Morales, Albert
  • Hartmann, Tobias
  • Colell Riera, Anna
Macroautophagy/autophagy failure with the accumulation of autophagosomes is an early neuropathological feature of Alzheimer disease (AD) that directly affects amyloid beta (Ab) metabolism. Although loss of presenilin 1 function has been reported to impair lysosomal function and prevent autophagy flux, the detailed mechanism leading to autophagy dysfunction in AD remains to be elucidated. The resemblance between pathological hallmarks of AD and Niemann-Pick Type C disease, including endosome-lysosome abnormalities and impaired autophagy, suggests cholesterol accumulation as a common link. Using a mouse model of AD (APP-PSEN1-SREBF2 mice), expressing chimeric mousehuman amyloid precursor protein with the familial Alzheimer Swedish mutation (APP695swe) and mutant presenilin 1 (PSEN1-dE9), together with a dominant-positive, truncated and active form of SREBF2/SREBP2 (sterol regulatory element binding factor 2), we demonstrated that high brain cholesterol enhanced autophagosome formation, but disrupted its fusion with endosomal-lysosomal vesicles. The combination of these alterations resulted in impaired degradation of Ab and endogenous MAPT (microtubule associated protein tau), and stimulated autophagy-dependent Ab secretion. Exacerbated Ab-induced oxidative stress in APP-PSEN1-SREBF2 mice, due to cholesterol-mediated depletion of mitochondrial glutathione/mGSH, is critical for autophagy induction. In agreement, in vivo mitochondrial GSH recovery with GSH ethyl ester, inhibited autophagosome synthesis by preventing the oxidative inhibition of ATG4B deconjugation activity exerted by Ab. Moreover, cholesterol-enrichment within the endosomes-lysosomes modified the levels and membrane distribution of RAB7A and SNAP receptors (SNAREs), which affected its fusogenic ability. Accordingly, in vivo treatment with 2-hydroxypropyl-b-cyclodextrin completely rescued these alterations, making it a potential therapeutic tool for AD., This work was supported by Ministerio de Economía y Competitividad under Grant: SAF2013-47246-R to A.C., SAF2015-66515-R to A.M., SAF2015-69944-R to J.F-C.); FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); Fundació La Marató de TV3 (2014-0930); Instituto de Salud Carlos III under Grant PI13/00374 and PI16/00930 to M.M., US NIAAA under Center grant P50- AA-11999 from Research Center for Liver and Pancreatic Diseases to J.F. C. We also want to thank the support of the AGAUR (2014-SGR785) and CERCA Programme from the Generalitat de Catalunya. C.dD. has a FPU fellowship from Ministerio de Economía y Competitividad. This work was developed (in part) at the Centre Esther Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice

  • Alvarez-Sola, Gloria
  • Uriarte, Iker
  • Latasa, Maria U.
  • Jimenez, Maddalen
  • Barcena-Varela, Marina
  • Santamaría, Eva
  • Urtasun, Raquel
  • Rodriguez-Ortigosa, Carlos
  • Prieto, Jesús
  • Corrales, Fernando J.
  • Baulies, Anna
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Berraondo, Pedro
  • Fernández-Barrena, Maite G.
  • Berasain, Carmen
  • Ávila, Matías A.
The liver displays a remarkable regenerative capacity triggered upon tissue injury or resection. However, liver regeneration can be overwhelmed by excessive parenchymal destruction or diminished by pre-existing conditions hampering repair. Fibroblast growth factor 19 (FGF19, rodent FGF15) is an enterokine that regulates liver bile acid and lipid metabolism, and stimulates hepatocellular protein synthesis and proliferation. FGF19/15 is also important for liver regeneration after partial hepatectomy (PH). Therefore recombinant FGF19 would be an ideal molecule to stimulate liver regeneration, but its applicability may be curtailed by its short half-life. We developed a chimaeric molecule termed Fibapo in which FGF19 is covalently coupled to apolipoprotein A-I. Fibapo retains FGF19 biological activities but has significantly increased half-life and hepatotropism. Here we evaluated the proregenerative activity of Fibapo in two clinically relevant models where liver regeneration may be impaired: acetaminophen (APAP) poisoning, and PH in aged mice. The only approved therapy for APAP intoxication is N-acetylcysteine (NAC) and no drugs are available to stimulate liver regeneration. We demonstrate that Fibapo reduced liver injury and boosted regeneration in APAPintoxicated mice. Fibapo improved survival of APAP-poisoned mice when given at later time points, when NAC is ineffective. Mechanistically, Fibapo accelerated recovery of hepatic glutathione levels, potentiated cell growth-related pathways and increased functional liver mass. When Fibapo was administered to old mice prior to PH, liver regeneration was markedly increased. The exacerbated injury developing in these mice upon PH was attenuated, and the hepatic biosynthetic capacity was enhanced. Fibapo reversed metabolic and molecular alterations that impede regeneration in aged livers. It reduced liver steatosis and downregulated p21 and hepatocyte nuclear factor 4 α (Hnf4α) levels, whereas it stimulated Foxm1b gene expression. Together our findings indicate that FGF19 variants retaining the metabolic and growth-promoting effects of this enterokine may be valuable for the stimulation of liver regeneration., Work in the authors' laboratory is supported by CIBERehd and Grants from Instituto de Salud Carlos III (ISCIII) co-financed by 'Fondo Europeo de Desarrollo Regional' (FEDER) 'Una manera de hacer Europa', numbers: FIS PI13/00359, PI13/00385 and PI16/01126. Grants SAF2015-66515-R, SAF201569944-R, SAF 2016-75972 R from Ministerio de Economía y Competitividad, and the center grant P50AA011999 funded by NIAAA. 'Ramón y Cajal-I3' contract to MUL, Mineco-FPI Fellowship to MB-V. Marie Curie EU contract to MGF-B. Fundación M Torres; Fundación Eugenio Rodríguez Pascual; Fundación Mario Losantos; Fundación Familia Puig-Infante and Fundación Bancaria La CaixaHepacare Project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Differential role of cathepsins S and B in hepatic APC-mediated NKT cell activation and cytokine secretion

  • Mingo, Álvaro de
  • Gregorio, Estefanía de
  • Chandra, Shilpi
  • Colell Riera, Anna
  • Morales, Albert
  • Kronenberg, Mitchell
  • Marí, Montserrat
Natural killer T (NKT) cells exhibit a specific tissue distribution, displaying the liver the highest NKT/conventional T cell ratio. Upon antigen stimulation, NKT cells secrete Th1 cytokines, including interferon γ (IFNγ), and Th2 cytokines, including IL-4 that recruit and activate other innate immune cells to exacerbate inflammatory responses in the liver. Cysteine cathepsins control hepatic inflammation by regulating κB-dependent gene expression. However, the contribution of cysteine cathepsins other than Cathepsin S to NKT cell activation has remained largely unexplored. Here we report that cysteine cathepsins, cathepsin B (CTSB) and cathepsin S (CTSS), regulate different aspects of NKT cell activation. Inhibition of CTSB or CTSS reduced hepatic NKT cell expansion in a mouse model after LPS challenge. By contrast, only CTSS inhibition reduced IFNγ and IL-4 secretion after in vivo α-GalCer administration. Accordingly, in vitro studies reveal that only CTSS was able to control α-GalCer-dependent loading in antigen-presenting cells (APCs), probably due to altered endolysosomal protein degradation. In summary, our study discloses the participation of cysteine cathepsins, CTSB and CTSS, in the activation of NKT cells in vivo and in vitro, This study was funded by grants from the Instituto de Salud Carlos III (PI16/00930 to MM), Ministerio de Economía y Competitividad (SAF2013-47246-R to AC, SAF2015-66515-R to AM) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); by NIH grant R37 71922 (to MK). Fundació Marató de TV3 (to AC), AGAUR and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bone morphogenetic protein-9/activin-like kinase 1 axis a new target for hepatic regeneration and fibrosis treatment in liver injury

  • Marí, Montserrat
  • Morales, Albert
Bone morphogenetic protein-9 (BMP-9), a member of the transforming growth factor (TGF)-β family of cytokines, is preferentially expressed in the liver from where is secreted into the blood (1-3). BMP-9 and BMP-10 are high-affinity ligands for the type I receptor activin-like kinase 1 (ALK1), whose participation in liver fibrosis has been previously suggested, and activin type II receptor A (ActRIIA) a BMP type II receptor with undefined role in liver biology. Although BMP-9 promotes epithelial to mesenchymal transition in hepatocellular carcinoma (HCC) cells, correlating with HCC aggressiveness in patients, and the BMP-9/ALK1 signaling has been related to liver pathologies, little was known about BMP-9 specific functions in liver cells and, particularly, after hepatic injury., The study was funded by grants from Instituto de Salud Carlos III (PI16/00930 to M Marí); Ministerio de Economía y Competitividad (SAF2015-66515-R to A Morales); co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Melatonin induces mechanisms of brain resilience against neurodegeneration.

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Palomera-Ávalos, Verónica
  • Porquet, David
  • García de Frutos, Pablo
  • Franciscato Cozzolino, Silvia M.
  • Rodríguez-Farré, Eduard
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Cardoso, Bárbara R.
Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age‐related ailments. The increase in circulating levels of melatonin through dietary supplements intensifies its health benefits. Investigations in animal models have shown that melatonin protects against Alzheimer's disease (AD)‐like pathology, although clinical studies have not been conclusive. We hypothesized that melatonin induces changes in the brain that prevent or attenuate AD by increasing resilience. Therefore, we treated healthy nontransgenic (NoTg) and AD transgenic (3xTg‐AD) 6‐month‐old mice with a daily dose of 10 mg/kg of melatonin until 12 months of age. As expected, melatonin reversed cognitive impairment and dementia‐associated behaviors of anxiety and apathy and reduced amyloid and tau burden in 3xTg‐AD mice. Remarkably, melatonin induced cognitive enhancement and higher wellness level‐related behavior in NoTg mice. At the mechanism level, NF‐κB and proinflammatory cytokine expressions were decreased in both NoTg and 3xTg‐AD mice. The SIRT1 pathway of longevity and neuroprotection was also activated in both mouse strains after melatonin dosing. Furthermore, we explored new mechanisms and pathways not previously associated with melatonin treatment such as the ubiquitin‐proteasome proteolytic system and the recently proposed neuroprotective Gas6/TAM pathway. The upregulation of proteasome activity and the modulation of Gas6 and its receptors by melatonin were similarly displayed by both NoTg and 3xTg‐AD mice. Therefore, these results confirm the potential of melatonin treatment against AD pathology, by way of opening new pathways in its mechanisms of action, and demonstrating that melatonin induces cognitive enhancement and brain resilience against neurodegenerative processes., This study was supported by grants SAF2016‐77703‐R, SAF2015‐66515‐R and SAF2016‐81716‐REDC from Spanish MINECO and European Development Fund, and 2017‐SGR‐106 from AGAUR and the CERCA Programme of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

  • Tutusaus, Anna
  • Stefanovic, Milica
  • Boix, Loreto
  • Cucarull, Blanca
  • Blasco, Laura
  • García de Frutos, Pablo
  • Reig, Maria
  • Fernández-Checa, José C.
  • Marí, Montserrat
  • Colell Riera, Anna
  • Bruix, Jordi
  • Morales, Albert
Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however, their role in HCC therapy with sorafenib/regorafenib remains uncertain. BH3-mimetic ABT-263 (navitoclax) enhanced sorafenib activity, inducing cell death via a mitochondrial caspase-dependent mechanism, after BCL-xL/BCL-2 inhibition. Sorafenib-resistant hepatoma cells (HepG2R and Hep3BR) exhibited altered mRNA expression of BCL-2 and other anti-apoptotic family members, such as MCL-1, priming drug-resistant cancer cells to death by BH3-mimetics. ABT-263 restored sorafenib efficacy in sorafenib-resistant cell lines and HCC mouse models. Moreover, in mice xenografts from patient-derived BCLC9 cells, better tumor response to sorafenib was associated to higher changes in the BCL-2 mRNA pattern. HCC non-treated patients displayed altered BCL-2, MCL-1 and BCL-xL mRNA levels respect to adjacent non-tumoral biopsies and an increased BCL-2/MCL-1 ratio, predictive of navitoclax efficacy. Moreover, regorafenib administration also modified the BCL-2/MCL-1 ratio and navitoclax sensitized hepatoma cells to regorafenib by a mitochondrial caspase-dependent mechanism. In conclusion, sorafenib/regorafenib response is determined by BCL-2 proteins, while increased BCL-2/MCL-1 ratio in HCC sensitizes drug resistant-tumors against ABT-263 co-administration. Thus, changes in the BCL-2 profile, altered in HCC patients, could help to follow-up sorafenib efficacy, allowing patient selection for combined therapy with BH3-mimetics or early switch them to second line therapy., Study funded by grants from Instituto de Salud Carlos III (FIS PI15/00145 to M.R., FIS PI14/00962 to J.B., PI13/00374 and PI16/00930 to M.M., CIBEREHD and CIBERNED), Ministerio de Economía y Competitividad (SAF2015-69944-R to J.F.C., SAF2015- 66515-R to A.M. and P.G.F., and SAF2013-47246-R to A.C.) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); center grant P50- AA-11999 from Research Center for Liver and Pancreatic Diseases, US NIAAA to J.F.C.). Fundació Marató de TV3 (to A.C), AGAUR (2014_SGR_605 to J.B. and 2014_ SGR_785 to J.F.C.) and CERCA Programme / Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading

  • Baulies, Anna
  • Montero, Joan
  • Matías, Nuria
  • Insausti, Naroa
  • Terrones, Oihana
  • Basáñez, Gorka
  • Vallejo, Carmen
  • Conde de la Rosa, Laura
  • Martínez, Laura
  • Robles, David
  • Morales, Albert
  • Abián, Joaquín
  • Carrascal, Montserrat
  • Machida, Keigo
  • Kumar, Dinesh B.U.
  • Tsukamoto, Hidekazu
  • Kaplowitz, Neil
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Cancer cells exhibit mitochondrial cholesterol (mt-cholesterol) accumulation, which contributes to cell death resistance by antagonizing mitochondrial outer membrane (MOM) permeabilization. Hepatocellular mt-cholesterol loading, however, promotes steatohepatitis, an advanced stage of chronic liver disease that precedes hepatocellular carcinoma (HCC), by depleting mitochondrial GSH (mGSH) due to a cholesterol-mediated impairment in mGSH transport. Whether and how HCC cells overcome the restriction of mGSH transport imposed by mt-cholesterol loading to support mGSH uptake remains unknown. Although the transport of mGSH is not fully understood, SLC25A10 (dicarboxylate carrier, DIC) and SLC25A11 (2-oxoglutarate carrier, OGC) have been involved in mGSH transport, and therefore we examined their expression and role in HCC. Unexpectedly, HCC cells and liver explants from patients with HCC exhibit divergent expression of these mitochondrial carriers, with selective OGC upregulation, which contributes to mGSH maintenance. OGC but not DIC downregulation by siRNA depleted mGSH levels and sensitized HCC cells to hypoxia-induced ROS generation and cell death as well as impaired cell growth in three-dimensional multicellular HCC spheroids, effects that were reversible upon mGSH replenishment by GSH ethyl ester, a membrane permeable GSH precursor. We also show that OGC regulates mitochondrial respiration and glycolysis. Moreover, OGC silencing promoted hypoxia-induced cardiolipin peroxidation, which reversed the inhibition of cholesterol on the permeabilization of MOM-like liposomes induced by Bax or Bak. Genetic OGC knockdown reduced the ability of tumor-initiating stem-like cells to induce liver cancer. These findings underscore the selective overexpression of OGC as an adaptive mechanism of HCC to provide adequate mGSH levels in the face of mt-cholesterol loading and suggest that OGC may be a novel therapeutic target for HCC treatment., The work was supported by grants SAF-2014-57674-R, SAF2015- 66515-R and SAF-2015-69944-R from Plan Nacional de I+D, Spain and by the support of CIBEREHD; the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH; and support from AGAUR of the Generalitat de Catalunya2014- SGR785, 2011BE-DGRBE100599 and 2011BEDGRBE100971 and grant LINK0378 from CSIC. The CSIC/UAB Proteomics Laboratory of IIBBCSIC is a member of Proteored, PRB2-ISCIII and is supported by grant PT13/0001, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. We want to thank the Integrative Liver Cell Core (R24AA012885) for preparation of TICs., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress

  • Dios, Cristina de
  • Bartolessis, Isabel
  • Roca-Agujetas, Vicente
  • Barbero-Camps, Elisabet
  • Marí, Montserrat
  • Morales, Albert
  • Colell Riera, Anna
Familial early-onset forms of Alzheimer's disease (AD) are linked to overproduction of amyloid beta (Aβ) peptides, while decreased clearance of Aβ is the driving force leading to its toxic accumulation in late-onset (sporadic) AD. Oxidative modifications and defective function have been reported in Aβ-degrading proteases such as neprilysin (NEP) and insulin-degrading enzyme (IDE). However, the exact mechanisms that regulate the proteolytic clearance of Aβ and its deficits are largely unknown. We have previously showed that cellular cholesterol loading, by depleting the mitochondrial GSH (mGSH) content, stimulates Αβ-induced mitochondrial oxidative stress and promotes AD-like pathology in APP-PSEN1-SREBF2 mice. Here, using the same AD mouse model we examined whether cholesterol-enhanced mitochondrial oxidative stress affects NEP and IDE function. We found that brain extracts from APP-PSEN1-SREBF2 mice displayed increased presence of oxidatively modified forms of NEP and IDE, associated with impaired enzymatic activities. Both alterations were substantially recovered after an in vivo treatment with the cholesterol-lowering agent 2-hydroxypropyl-β-cyclodextrin. The recovery of the proteolytic activity after treatment was accompanied with a significant reduction of Aβ levels. Supporting these results, cholesterol-enriched SH-SY5Y cells were more sensitive to Aβ-induced impairment of IDE and NEP function in vitro. The rise of cellular cholesterol also stimulated the extracellular release of IDE by an unconventional autophagy-coordinated mechanism. Recovery of depleted pool of mGSH in these cells not only prevented the detrimental effect of Aβ on intracellular AβDPs activities but also had an impact on extracellular IDE levels and function, stimulating the extracellular Aβ degrading activity. Therefore, changes in brain cholesterol levels by modifying the mGSH content would play a key role in IDE and NEP-mediated proteolytic elimination of Aβ peptides and AD progression., This work was supported by the Ministerio de Economía y Competitividad, Spain [SAF2013-47246-R and RTI2018-095572-B-100 to A.C., SAF2015-66515-R to A.M.]; the FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea. “Una manera de hacer Europa”); the Fundació La Marató de TV3, Spain [2014-0930 to A.C.]; the Instituto de Salud Carlos III, Spain [PI16/00930 to M.M]; the Agencia de Gestió d’Ajuts Universitaris i de Recerca, Spain [2017_SGR_177]; and the CERCA Programme from the Generalitat de Catalunya, Spain. C.dD. has a FPU fellowship from Ministerio de Ciencia, Innovación y Universidades, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

La ausencia de linfocitos NKT agrava la esteatohepatitis n alcohólica (EHNA) experimental en ratones macho

  • Gregorio, Estefanía de
  • Tutusaus, Anna
  • Morales, Albert
  • Marí, Montserrat
Trabajo presentado en el 44º Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH), celebrado en Madrid (España), del 20 al 22 de febrero de 2019, Introducción: La enfermedad del hígado graso no alcohólico afecta al 25% de la población adulta y es en la actualidad la enfermedad hepática más común en el mundo. Su forma más progresiva, la esteatohepatitis no alcohólica (EHNA), se caracteriza por la presencia de daño a los hepatocitos, fibrosis e inflamación. Las células NKT dependientes de CD1d abarcan dos tipos celulares diferenciados, las células iNKT, o NKT invariantes, y las células NKT de tipo II, con características inmunomoduladoras distintas. En general, las células iNKT parecen contribuir a la inflamación hepática, mientras que las células NKT tipo II son protectoras. En el contexto de la EHNA, el papel de las células NKT dependientes de CD1d es controvertido, ya que se han descrito observaciones contradictorias. Métodos: Ratones salvajes (WT) o deficientes en CD1d (CD1dKO) de 6-8 semanas, machos y hembras de la cepa BALBc, fueron alimentados 6 semanas con dieta alta en grasa (60% kcal) con restricción de metionina y deficiencia en colina (HFCD) para inducir EHNA. El contenido de colágeno se midió mediante determinación de hidroxiprolina y tinción con Sirius Red seguido de cuantificación del software de imagen. La activación de HSC, la inflamación hepática y la producción de citoquinas se midieron mediante qPCR y western blot. Resultados: La dieta HFCD indujo un daño hepático (aumento de ALT) acompañado de esteatosis, fibrosis e inflamación significativas tanto en ratones WT como en los ratones CD1d-KO. Al analizar, tras el periodo de administración de dieta HFCD, el cociente peso del hígado/peso corporal éste era significativamente inferior en los ratones CD1d-KO frente a los ratones WT. La dieta HFCD indujo un aumento de los depósitos de triglicéridos y colesterol intrahepáticos tanto en animales WT como en CD1d-KO. Mientras que los niveles de triglicéridos eran similares en ambos grupos, los niveles de colesterol eran superiores en los animales CD1d-KO vs WT+HFCD. Todas estas características fueron comunes para ratones hembras y machos deficientes en CD1d. Sin embargo, al analizar los parámetros referentes a fibrosis e inflamación encontramos claras diferencias entre sexos. Los CD1d-KO machos mostraron una presencia de fibras de colágeno acompañada de una mayor expresión de a-SMA y COL1A1 mRNA respecto a los machos WT+HFCD. Paralelamente, los ratones macho CD1d-KO+HFCD mostraron un claro incremento de la expresión de genes inflamatorios IL-6, MCP-1 y una disminución del gen anti-inflamatorio IL-10 respecto a los machos WT. Por el contrario, ratones hembra deficientes en CD1d +HFCD mostraron unos parámetros de fibrosis e inflamación similares a las hembras WT con dieta. Conclusiones: La ausencia de células NKT agrava la EHNA en ratones macho. La disparidad de resultados entre ambos sexos resalta la importancia de realizar estudios comparativos de género particularmente en patologías hepáticas donde las NKTs puedan hallarse involucradas., Este trabajo de investigación ha sido financiado con las subvenciones PI16/00930 para M.M. concedidas por el Instituto de Salud Carlos III y SAF2015-66515-R para A.M., Ministerio de Economía y Competitividad, y co-financiado por el FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

La proteína BCL-xL regula la resistencia adquirida a regorafenib del carcinoma hepatocellular (HCC) sensibilizando a miméticos de BH3 en terapia experimental

  • Cucarull, Blanca
  • Tutusaus, Anna
  • Boix, Loreto
  • Reig, Maria
  • Bruix, Jordi
  • Morales, Albert
Trabajo presentado en el 44º Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH), celebrado en Madrid (España), del 20 al 22 de febrero de 2019, Introducción: El inhibidor multiquinasa regorafenib tiene una eficacia clínica limitada en el tratamiento del carcinoma hepatocelular avanzado (HCC) debido a la aparición de resistencia celular adquirida. El daño mitocondrial inducido por regorafenib no ha sido estudiado en la terapia del HCC, a diferencia de la toxicidad mitocondrial inducida por sorafenib. La posible efectividad de miméticos de BH3, inhibidores de proteínas BCL-2 específicas, en combinación con regorafenib es desconocida y podría aportar nuevas dianas en el tratamiento del HCC. Métodos: Se trataron líneas celulares de hepatoma HepG2 y Hep3B con regorafenib y miméticos de BH3 (inhibidor BCL- xL: A-1331852 e inhibidor BCL-2: ABT-199). Se realizaron silenciamientos con siRNAs control, siBCL-2 y siBCL-xL, así como Western blots y qPCRs. La funcionalidad mitocondrial, la activación de caspasas y la inducción de apoptosis se analizaron en células de hepatoma tratadas con regorafenib. Se analizó la efectividad antitumoral del regorafenib en terapias con miméticos de BH3 en esferoides tumorales hepáticos (Hep3B/LX2), y en el crecimiento tumoral de xenoinjertos (BCLC9) en ratones. Resultados: Las células Hep3B exhibieron cambios en varias proteínas del sistema de BCL-2, como BCL-xL, MCL-1 o BIM tras exposición a regorafenib indicativos de una adaptación en las células resistentes. El silenciamiento de Hep3B con siRNAs frente a BCL-2 y BCL-xL, principales proteínas antiapoptóticas responsables de la resistencia BCL-2-dependiente, demostró que la reducción de BCL-xL sensibiliza las células de hepatoma frente al regorafenib. Utilizando miméticos de BH3 específicos de BCL-2 (ABT-199) y BCL-xL (A1331852) se observó un claro incremento de la muerte celular inducida por regorafenib (HepG2 y Hep3B) por un mecanismo mitocondrial caspasa-dependiente únicamente tras del inhibición de BCL-xL. Prueba de ello, la coadministración de A-1331852 incrementó la reducción del potencial de membrana mitocondrial inducida por regorafenib, la liberación de citocromo c y la actividad caspasa-3. De forma similar, esferoides tumorales hepáticos tratados con regorafenib manifestaron reducción de volumen, pérdida de potencial de membrana e incremento de la muerte celular tras la adición del inhibidor de BCL-xL A-1331852. Además, xenoinjertos de ratones de células BCLC9 derivadas de pacientes mostraron una regulación al alza de BCL-xL y BIM tras tratamiento con regorafenib evidenciando la relevancia de esta adaptación mitocondrial y mostrando mecanismos de muerte celular tras análisis transcriptómico diferenciados a los inducidos por sorafenib. La coadministración de A-1331852 potenció los efectos del regorafenib disminuyendo el crecimiento tumoral. Conclusiones: El regorafenib induce cambios en los niveles de proteínas de la familia de BCL-2, promoviendo sensibilización mitocondrial utilizable por miméticos de BH3 como A-1331852 para incrementar la eficacia del tratamiento del HCC., Trabajo de investigación financiado por Fondo de Investigaciones Sanitarias, Gobierno de España, confinanciado por FEDER (SAF2015-66515-R para A.M. y PI16/00930 para M.M.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recent Insights into the Mitochondrial Role in Autophagy and Its Regulation by Oxidative Stress

  • Roca-Agujetas, Vicente
  • Dios, Cristina de
  • Lestón, Laura
  • Marí, Montserrat
  • Morales, Albert
  • Colell Riera, Anna
Autophagy is a self-digestive process that degrades intracellular components, including damaged organelles, to maintain energy homeostasis and to cope with cellular stress. Autophagy plays a key role during development and adult tissue homeostasis, and growing evidence indicates that this catalytic process also has a direct role in modulating aging. Although autophagy is essentially protective, depending on the cellular context and stimuli, autophagy outcome can lead to either abnormal cell growth or cell death. The autophagic process requires a tight regulation, with cellular events following distinct stages and governed by a wide molecular machinery. Reactive oxygen species (ROS) have been involved in autophagy regulation through multiple signaling pathways, and mitochondria, the main source of endogenous ROS, have emerged as essential signal transducers that mediate autophagy. In the present review, we aim to summarize the regulatory function of mitochondria in the autophagic process, particularly regarding the mitochondrial role as the coordination node in the autophagy signaling pathway, involving mitochondrial oxidative stress, and their participation as membrane donors in the initial steps of autophagosome assembly., Research support was provided by Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE) (RTI2018-095572-B-100; RTI2018-095672-B-I00; SAF2015-66515-R); the Instituto de Salud Carlos III (PI16/00930 and PI19/01410); Fundació La Marató de TV3 (2014-0930); AGAUR (2017_SGR_177); and CERCA Programme from the Generalitat de Catalunya. C.dD. has a FPU fellowship from MCIU.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target

  • Tutusaus, Anna
  • Gregorio, Estefanía de
  • Cucarull, Blanca
  • Cristóbal, Helena
  • Aresté, Cristina
  • Graupera, Isabel
  • Coll, Mar
  • Colell Riera, Anna
  • Gausdal, Gro
  • Lorens, James B.
  • García de Frutos, Pablo
  • Morales, Albert
  • Marí, Montserrat
Background and Aims: GAS6 signaling, through the TAM receptor tyrosine kinases AXL and MERTK, participates in chronic liver pathologies. Here, we addressed GAS6/TAM involvement in Non-Alcoholic SteatoHepatitis (NASH) development. Methods: GAS6/TAM signaling was analyzed in cultured primary hepatocytes, hepatic stellate cells (HSC) and Kupffer cells (KCs). Axl, Mertk and wild-type C57BL/6 mice were fed with Chow, High Fat Choline-Deficient Methionine-Restricted (HFD) or methionine-choline-deficient (MCD) diet. HSC activation, liver inflammation and cytokine/chemokine production were measured by qPCR, mRNA Array analysis, western blotting and ELISA. GAS6, soluble AXL (sAXL) and MERTK (sMERTK) levels were analyzed in control individuals, steatotic and NASH patients. Results: In primary mouse cultures, GAS6 or MERTK activation protected primary hepatocytes against lipid toxicity via AKT/STAT-3 signaling, while bemcentinib (small molecule AXL inhibitor BGB324) blocked AXL-induced fibrogenesis in primary HSCs and cytokine production in LPS-treated KCs. Accordingly; bemcentinib diminished liver inflammation and fibrosis in MCD- and HFD-fed mice. Upregulation of AXL and ADAM10/ADAM17 metalloproteinases increased sAXL in HFD-fed mice. Transcriptome profiling revealed major reduction in fibrotic- and inflammatory-related genes in HFD-fed mice after bemcentinib administration. HFD-fed Mertk mice exhibited enhanced NASH, while Axl mice were partially protected. In human serum, sAXL levels augmented even at initial stages, whereas GAS6 and sMERTK increased only in cirrhotic NASH patients. In agreement, sAXL increased in HFD-fed mice before fibrosis establishment, while bemcentinib prevented liver fibrosis/inflammation in early NASH. Conclusion: AXL signaling, increased in NASH patients, promotes fibrosis in HSCs and inflammation in KCs, while GAS6 protects cultured hepatocytes against lipotoxicity via MERTK. Bemcentinib, by blocking AXL signaling and increasing GAS6 levels, reduces experimental NASH, revealing AXL as an effective therapeutic target for clinical practice., This study was funded by grants from Instituto de Salud Carlos III (PI16/00930 and PI19/01410 to Montserrat Marí) and CIBEREHD; Ministerio de Economía y Competitividad (SAF2015-66515-R and RTI2018-095672-B-I00 to Albert Morales and Pablo García de Frutos, and RTI2018-095572-B-100 to Anna Colell), and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea), Fundació Marató de TV3 (to Pablo García de Frutos), AGAUR (2017_SGR_177 to Albert Morales), and CERCA Programme/ Generalitat de Catalunya